July 5, 2022
Life Sciences
  • Pfizer’s success in developing COVID-19 vaccines and medicines has not only helped the company yield record revenue but has also given the drugmaker unusual weight in determining U.S. health policy. Based on internal research conducted by Kaiser Health News, the company’s executives have frequently announced the next stage in the fight against the pandemic before government officials have had time to study the issue, annoying many experts in the medical field and leaving some patients unsure whom to trust. (Article here)